Seaweed weight-loss product
This article was originally published in The Tan Sheet
Executive Summary
A patent-pending extract of fucoxanthin, a compound found in brown seaweed, demonstrates significant weight loss in obese women, according to results of a double-blind, placebo-controlled study of 140 obese females. Specialty Nutrition Group's LipoxanThin product showed "significant reduction in liver fat, body fat and body weight versus placebo after 16 weeks," Sergey Grachev, MD, Professor of Medicine, First Medical Academy and Institute of Immunopathology, Russian Academy of Natural Sciences, et al., state. The study is pending publication by the Russian Academy of Natural Sciences. A recent Japanese study also demonstrating promising results for the fat-fighting effects of fucoxanthin (1"The Tan Sheet" Sept. 18, 2006, p. 11)...
You may also be interested in...
Nutraceutical R&D In Brief
Vitamin D and pancreatic cancer: Vitamin D supplementation cuts the risk of pancreatic cancer nearly in half, according to a study in the September Cancer Epidemiology Biomarkers & Prevention. Halcyon Skinner, PhD, Feinberg School of Medicine, Northwestern University, et al., find that taking the U.S. recommended daily allowance of vitamin D (400 IU) reduces the risk of pancreatic cancer by 43%. Those who consume less than 150 IU/day experience a 22% reduced risk of cancer. No significant benefit was found for those consuming more than 400 IU/day. Skinner et al. analyzed data on 46,771 men age 40-75 and 75,427 women age 38-65. The authors recommend further research to determine whether vitamin D ingestion from dietary sources is preferable to multivitamin supplementation. Some multivitamins contain retinol, an antagonist that influences vitamin D's ability to affect mineral balances and bone integrity, Skinner et al. note...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.